News

BrainStorm Cell Therapeutics has signed an agreement with the University of California Irvine Medical Center (UCI) to start enrolling patients for an upcoming Phase 3 clinical trial evaluating whether NurOwn can improve functional impairment in amyotrophic lateral sclerosis (ALS) patients. NurOwn is made of mesenchymal stem cells…

Healthcare providers may now begin researching the insurance benefits process for patients in advance of the upcoming availability of Radicava (edaravone), an approved treatment for amyotrophic lateral sclerosis (ALS), according to the therapy’s distributor in the U.S., Mitsubishi Tanabe Pharma America. The U.S. Food and Drug Administration (FDA)…

Cytokinetics recently announced the start of a Phase 2 clinical trial investigating a new therapy candidate (CK-2127107) for the potential treatment of amyotrophic lateral sclerosis (ALS). The Phase 2 FORTITUDE-ALS (NCT03160898) study will soon be…

The U.S. Food and Drug Administration has granted fast track status to FLX-787, Flex Pharma‘s treatment for severe muscle cramps in amyotrophic lateral sclerosis. Flex designed FLX-787 to interfere with transient receptor potential ion channels that are believed to play a role in nervous system pain and inflammation.

Scientists have known for some time that abnormal DNA repetitions in the C9orf72 gene contribute to neuron death in ALS and frontotemporal dementia. Now they have learned how it happens: The anomalies leave DNA susceptible to damage, prompting a cell repair mechanism to become over-active. That hyperactivity cause neuron deaths.

Brainstorm Cell Therapeutics has received a $16 million grant from a state agency known as the California Institute for Regenerative Medicine to develop a Phase 3 clinical trial of its ALS stem-cell therapy NurOwn. NurOwn is based on mesenchymal stem cells, which can transform themselves into various types of cells. Brainstorm…

Researchers have discovered a natural mechanism that can help prevent the formation of harmful protein clumps that contribute to the development of amyotrophic lateral sclerosis (ALS), according to results of a new study. They also gained new insights into the formation of the protein clumps known as TDP-43 protein aggregates that…

RNA molecules that are not supposed to leave the cell nucleus might be responsible for driving neuronal cell death in people with amyotrophic lateral sclerosis (ALS), researchers from England’s University of Sheffield report in a study that suggests a way to prevent that from happening. The research team discovered just how…

Massachusetts General Hospital in Boston and California Pacific Medical Center in San Francisco will be among the sites where ALS patients will take in a Phase 3 clinical trial of BrainStorm Cell Therapeutics’ NurOwn. The trial will begin after the company receives approval from the U.S. Food and Drug Administration and…

A musical instrument that can be played only with brain activity may empower and rehabilitate patients with ALS and other motor diseases. Invoking brain scans known as electroencephalograms, University of Washington researchers have dubbed the musical device they created an Encephalophone. The article they wrote about it, titled “A Novel Musical…